Generated by AI
Takeda Pharmaceutical Co Ltd ADR is a sponsored American depositary receipt representing shares of Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company. Takeda develops, manufactures, markets, and out-licenses prescription medicines across major therapeutic areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. Its portfolio is centered on specialty treatments and biologic medicines used in hospital, clinic, and outpatient settings, with commercial operations spanning Japan, the United States, Europe, and other international markets. The company also supports research and development, regulatory activities, and global manufacturing for small-molecule and biologic products. Takeda Pharmaceutical Co Ltd ADR provides U.S. investors with access to a diversified healthcare business focused on drug discovery, clinical development, and worldwide pharmaceutical commercialization.
Website1-1, Nihonbashi-Honcho 2-chome
Chuo, 103-8668
Japan
The latest articles about TAK.
OSAKA, Japan & CAMBRIDGE, Mass., November 12, 2026--ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1, is Now Available in the United States
Summary of May 25's posts. Generated by AI.
Summary of May 15's posts. Generated by AI.
Summary of Jun 18's posts. Generated by AI.
Investors talking about TAK also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.